Blood dyscrasias and the pharmaceutical industry: screening surveillance and monitoring, and future drug development.
D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D016903:Drug Monitoring; D006801:Humans; D010265:Paraproteinemias / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing